Small and mid-size biopharmaceutical companies need an experienced CDMO that can help them accelerate their products from concept to treatment more than ever
Thermo Fisher to identify local labs that will be using its NGS technology and Pfizer will explore ways to enable affordable patient access for NGS testing.
OLUMIANT is the first JAK inhibitor FDA-approved for the treatment of COVID-19 in certain hospitalized adults requiring various degrees of oxygen support.
Supports clinical trial continuity for biopharma companies during COVID-19 pandemic by transferring clinical trial patients to AES’ dedicated research sites